L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:796244 CAPLUS
TITLE: 3-Cycloalkyl-substituted GABA compounds as **gabapentin** analogs.
AUTHOR(S): Belliotti, Thomas; Wustrow, David J.; Su, Ti-Zhi; Suman-Chauhan, Nirmala
CORPORATE SOURCE: Medicinal Chemistry, Warner Lambert, Ann Arbor, MI, 48105, USA
SOURCE: Abstracts of Papers - American Chemical Society (2000), 220th, MEDI-245
CODEN: ACSRAL; ISSN: 0065-7727
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal; Meeting Abstract
LANGUAGE: English

AB 3-Cycloalkyl-substituted GABA compds. as **gabapentin** analogs In recent years, **Gabapentin** (I) has become a premier treatment for epilepsy and neuropathic pain. As part of a program to discover compds. with increased bioavailability and potency, we synthesized a series of 3-cycloalkyl GABA analogs (II). The compds. were tested for their ability to displace [3H]**gabapentin** from the a2d subunit of calcium channels. Compds. were also tested for their ability to **compete** with leucine at the system L amino acid transporter. The synthesis and SAR of the compds. will be discussed.

WEST

Print Selection

Help | Clear | Cancel | Print | Print First Page

Select?	Document ID	Section(s)	Page(s)	# Pages to print	Database
☑	WO200076958A	all	all	N/A	USPT,PGPB,JPAB,EPAB,DWPI
☑	WO200031020A	all	all	N/A	USPT,PGPB,JPAB,EPAB,DWPI
☑	6521650	all	all	12	USPT,PGPB,JPAB,EPAB,DWPI

Building: cm1 Room: 11e14 Printer: gbegptr

Main Menu | Logout

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:351162 CAPLUS
DOCUMENT NUMBER: 133:790
TITLE: New use of glutamate antagonists for the treatment of cancer
INVENTOR(S): Ikonomidou, Hrissanthi
PATENT ASSIGNEE(S): Germany
SOURCE: Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1002535	A1	20000524	EP 1998-250380	19981028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 9964750	A1	20000515	AU 1999-64750	19991022
EP 1124553	A1	20010822	EP 1999-952622	19991022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002528415	T2	20020903	JP 2000-578005	19991022

PRIORITY APPLN. INFO.: EP 1998-250380 A 19981028
WO 1999-EP8004 W 19991022

AB New therapies can be devised based upon a demonstration of the role of glutamate in the pathogenesis of cancer. Inhibitors of the interaction of glutamate with the AMPA, kainate, or NMDA receptor complexes are likely to be useful in treating cancer and can be formulated as pharmaceutical compns. They can be identified by appropriate **screens**.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

	L #	Hits	Search Text	DBs	Time Stamp
1	L1	4	alpha-2-delta	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/12 09:09
2	L2	5428	calcium adj1 channel	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/12 09:08
3	L3	784353	(inhibit$4 or compete or competi$4)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/12 09:33
4	L4	4841	gabapentin or gaba or gbp	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/12 09:10
5	L5	1393	l3 with l4	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/12 09:13

	L #	Hits	Search Text	DBs	Time Stamp
6	L6	42	l5 with l2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/12 09:10
7	L7	205	l3 with l4 with (bind or binding)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/12 09:13
8	L8	125079	(compete or competi$4)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/12 09:33
9	L9	3	l8 with l4 with l2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/12 09:34
10	L10	84	l8 with l4	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/12 09:34